• Income Statement
• Balance Sheet
• Cash Flow
• Ratios
• Market Data
• Valuation

Drugs Made In America Acquisition Corp. (DMAA)

Q2-CY2026

Q1-CY2026

Q4-CY2025

Q3-CY2025

Q2-CY2025

Q1-CY2025

Q4-CY2024

Q3-CY2024

Q2-CY2024

Q1-CY2024

Q4-CY2023

Q3-CY2023

Q2-CY2023

Q1-CY2023

Q4-CY2022

Q3-CY2022

Q2-CY2022

Q1-CY2022

Q4-CY2021

Q3-CY2021

Q2-CY2021

Q1-CY2021

Q4-CY2020

Q3-CY2020

Q2-CY2020

Q1-CY2020

Q4-CY2019

Q3-CY2019

Q2-CY2019

Q1-CY2019

Q4-CY2018

Q3-CY2018

Q2-CY2018

Q1-CY2018

Q4-CY2017

Q3-CY2017

Q2-CY2017

Q1-CY2017

Q4-CY2016

Q3-CY2016

Q2-CY2016

Q1-CY2016

Q4-CY2015

Q3-CY2015

Q2-CY2015

Q1-CY2015

Q4-CY2014

Q3-CY2014

Q2-CY2014

Balance Sheet Date

2025-Dec-31

2025-Sep-30

2025-Jun-30

2025-Mar-31

2024-Dec-31

Fiscal Period

Q4-FY2025

Q3-FY2025

Q2-FY2025

Q1-FY2025

Q4-FY2024

Total Revenue

QoQ%

YoY%

Cost Of Revenue

Gross Profit

Gross Margin

Operating Expenses

2,116,766$

263,703$

131,919$

330,925$

144,928$

Operating Income

(2,089,466$)

(263,703$)

(131,919$)

(330,925$)

(144,928$)

Operating Margin

Interest Income

2,302,424$

2,448,266$

2,420,498$

1,585,468$

Interest Expenses

Income Before Tax

212,958$

2,184,563$

2,288,579$

1,254,543$

(144,928$)

Tax Expenses

Net Income

212,958$

2,184,563$

2,288,579$

1,254,543$

(144,928$)

Profit Margin

TTM

Earnings to Minority

Earnings to Common Shareholders

212,958$

2,184,563$

2,288,579$

1,254,543$

(144,928$)

QoQ%

(90.25%)

(4.55%)

82.42%

YoY%

1,607.34%

Earnings Per Share, Basic

Earnings Per Share, Diluted

Unlevered FCF Per Share, Basic

Unlevered FCF Per Share, Diluted

Average Shares, Basic

Average Shares, Diluted

EBIT

212,958$

2,184,563$

2,288,579$

1,254,543$

(144,928$)

EBITDA

212,958$

2,184,563$

2,288,579$

1,254,543$

(144,928$)

Copy Table ✓